

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

LANOVA MEDICINES DEVELOPMENT CO., LTD.
999 Cailun Road, Building 1, Floor 5, Pudong New District
Shanghai 201203, China

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for all countries in and to this invention relating to

ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF

as set forth in PCT International Application

check one ☐ executed concurrently herewith,
 ☐ executed on _____,
 ☒ Serial No.: PCT/CN2022/100315 Filed June 22, 2022

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent all countries for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in all countries, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, (e) all post-grant proceedings including but not limited to post-grant review, ex parte reexamination and inter partes review, and (f) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY GRANTS ASSIGNEE the right to sue for past, present and future infringement, and the right to collect and receive any damages, royalties, or settlement for such past, present and future infringements and any and all causes of action relating to any of the inventions or discoveries described in this invention.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR/INVENTOR(S):

Signature: Runsheng Li

Name: Runsheng Li

Date: June 8, 2023

Signature: Wentao Huang

Name: Wentao Huang

Date: June 8, 2023

Signature: Yifan Li

Name: Yifan Li

Date: June 8, 2023

ASSIGNEE: LaNova Medicines Development Co., Ltd.

Signature: Yunwen Zhao.

Name: Yunwen Zhao

Title: Senior Director of Legal & Compliance

Date: June 8, 2023